Shi Minjun, Ye Bo
Department of Thoratic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Zhongguo Fei Ai Za Zhi. 2024 Sep 20;27(9):685-690. doi: 10.3779/j.issn.1009-3419.2024.106.22.
Invasive mucinous adenocarcinoma (IMA) is a special type of lung adenocarcinoma that accounts for 2% to 10% of all lung adenocarcinoma. Surgical treatment is preferred for IMA, and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease. IMA has unique prognostic, imaging and molecular features. The incidence of IMA is very low, so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis. This article reviews and discusses the imaging, clinicopathological features, treatment methods and prognosis of IMA. .
浸润性黏液腺癌（IMA）是肺腺癌的一种特殊类型，占所有肺腺癌的2%至10%。IMA首选手术治疗，传统化疗药物和靶向治疗药物对该疾病疗效不佳。IMA具有独特的预后、影像学和分子特征。IMA的发病率很低，因此胸外科医生可能对该疾病缺乏了解，并将其误诊为肺炎和肺结核等良性疾病。本文对IMA的影像学、临床病理特征、治疗方法及预后进行综述和讨论。
